Notified bodies should interrupt the timeline of a conformity assessment activity where the completion of such an activity depends upon further information to be provided by the manufacturer. The timeline should also be interrupted where the completion of the activity depends on the contribution of the European Medicinal Agency (EMA), a regulatory authority, an expert panel or of an EU reference laboratory, as long as the notified bodies’ activities depend exclusively on those contributions.
Recital 18, Regulation (EU) 2026/977
In forcesince 4 May 2026